CN107397738A - A kind of compound medicament composition with function of relieving cough and calming asthma and application thereof - Google Patents
A kind of compound medicament composition with function of relieving cough and calming asthma and application thereof Download PDFInfo
- Publication number
- CN107397738A CN107397738A CN201710604115.5A CN201710604115A CN107397738A CN 107397738 A CN107397738 A CN 107397738A CN 201710604115 A CN201710604115 A CN 201710604115A CN 107397738 A CN107397738 A CN 107397738A
- Authority
- CN
- China
- Prior art keywords
- medicine
- composition
- asthma
- relieving
- cough
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to natural medicine field, discloses a kind of compound medicament composition with function of relieving cough and calming asthma and application thereof.The active component of the compound medicament composition be by mass ratio be 1:1~1:10 6 gingerols and ursolic acid composition.Both drug combinations antibechic, relieving asthma, eliminating the phlegm, functions of detumescence, relieving inflammation and strengthen immunity etc. have good activity.
Description
Technical field
The invention belongs to natural medicine field, more particularly to a kind of compound medicament composition with function of relieving cough and calming asthma and
Its purposes.
Background technology
Chronic bronchitis belongs in exopathogen more invades, caused by endogenous cough, and eating and drinking without temperance, the dysfunction of the spleen in transport, raw wet poly-
Phlegm；Internal organ imbalance, lung defend deficiency, cause phlegm erosion resistance lung, show as the diseases such as cough, expectoration, asthma, control suitable detoxicating, relieving inflammation, cough-relieving
Resolving sputum, relieving asthma.Modern medicine believes that, chronic bronchitis has infection, chemical factors, climate change, intolerance factors etc. more
Cause chronic bronchitis.Treatment is relievingd asthma frequently with infection control, eliminating phlegm and relieving cough, spasmolysis, either traditional medicine or modern times
Medical science, the sick treatment have obvious uniformity.
Ginger and rhizoma zingiberis are respectively zingiber Zingiber officinale Rosc. new fresh quench stem and dry root
Stem, it is conventional Chinese medicine.The clinical practice of ginger is quite extensive, external also higher to its degree of concern.In recent years, for ginger and its
The chemistry and pharmacology of main active are reported compared with horn of plenty.6-gingerol (6-gingerol, 6G) is the volatile ingredient in ginger
One of, its molecular formula is：C17H26O4, molecular weight 294.4, for yellowish white to white powder thing or crystal, ethanol is soluble in,
It is insoluble in water.Document report 6-gingerol have cardiac stimulant, prevention and cure of cardiovascular disease, antiplatelet or antithrombotic, anti-inflammatory, it is anti-oxidant,
Preventing or arresting vomiting, relieving fainting, relax contracting blood vessel and the bioactivity such as antitumor.Ursolic acid (Ursolic Acid, abbreviation UA) is 3 beta-hydroxies-bear
Fruit -12- alkene -28- acid (3 β-hydroxy-urs-12-en-28-oic acid), belongs to pentacyclic triterpenoid, and it is certainly
Natural active compound distributed more widely in right boundary, such as the leaf of goatweed royal paulownia, the fruit of madder wort cape jasmine, dragon
Courage section plant humidogene flower bud, oleaceae plant glossy privet a variety of not equal platymisciums such as leaf in.Numerous studies show that ursolic acid has
Antitumor, anti-inflammatory, liver protection is calm, the multiple biological activities such as anti-oxidant.The inventors discovered that optimization blends combination 6-gingerol and
Ursolic acid, there is good cough-relieving, antibechic, antiasthmatic effect.
The content of the invention
In order to overcome shortcoming and defect present in prior art, primary and foremost purpose of the invention is that providing one kind has only
The compound medicament composition of cough antiasthmatic effect；The compound medicament composition is made up of 6-gingerol and ursolic acid.
Another object of the present invention is to provide a kind of system of the above-mentioned compound medicament composition with function of relieving cough and calming asthma
Preparation Method.
It is still another object of the present invention to provide a kind of answering for above-mentioned compound medicament composition with function of relieving cough and calming asthma
With.
The purpose of the present invention is achieved through the following technical solutions：
A kind of compound medicament composition with function of relieving cough and calming asthma, the active component of the compound medicament composition is by 6-
Gingerol and ursolic acid composition.
Preferably, the mass ratio of the 6-gingerol and ursolic acid is 1:1~1:10.
More preferred, the mass ratio of the 6-gingerol and ursolic acid is 1:1~1:4.
The compound medicament composition also contains pharmaceutically acceptable carrier.
The compound medicament composition is prepared by conventional fabrication process.
A kind of above-mentioned compound medicament composition with function of relieving cough and calming asthma prepare cough-relieving, antibechic, relieving asthma, eliminating the phlegm,
Purposes in functions of detumescence, relieving inflammation and the medicine of strengthen immunity.
The compound medicament composition with function of relieving cough and calming asthma can be used for the medicine of mammal including people
Treatment.
The present invention has the advantages of following prominent and beneficial effect compared with prior art：This compound medicament composition has
Antibechic, relieving asthma, eliminating the phlegm, functions of detumescence, relieving inflammation and strengthen immunity etc. have good activity.
Embodiment
With reference to embodiment, the present invention is described in further detail, but the implementation of the present invention is not limited to this.
Embodiment 1：The preparation of composition of medicine capsule
By different quality ratio (1：1,1:2.5,1：5,1：10) after 6-gingerol (6G) and ursolic acid (UA) is well mixed, add
Enter medical starch, 35% calcium monohydrogen phosphate is placed in trough type mixing machine and mixed, add 50% mass concentration ethanol solution make in right amount
Wetting agent, which is mixed thoroughly, is made suitable softwood, examines softwood quality to make up to hand and pinches agglomerating, the i.e. scattered of strandings is advisable.With 30 mesh nylon mesh
Wet granular processed, aeration-drying to moisture is about 1.5% within 55 DEG C, and with 20 mesh sieve whole grains, dry granular adds 1.5% superfine silica gel powder,
Always it is mixed in " v " type mixer even, is filled after intermediate products passed examination with Autocapsulefillingmachine, is prepared into glue
Capsule, it is respectively designated as relieving cough and asthma composition of medicine capsules A, B, C, D.
Embodiment 2：Relieving cough and asthma composition of medicine mouse ammoniacal liquor draws cough effect and investigated
The mouse for being about 20g by body weight, coughed with ammoniacal liquor Induced by Stimulation, cough number is screening up to more than 3 times in 3min
It is qualified.Take and screen qualified mouse, be randomly divided into six groups.The medicine group relieving cough and asthma composition of medicine that ig embodiments 1 obtain respectively
500mg/kg, positive controls SC Codeine Hydrochloride 60mg/kg, control group then ig equivalent distilled water.1 time a day, for three days on end
(except Codeine Hydrochloride), after last dose 1h (Codeine Hydrochloride 30min), carried out by screening technique, count every group of mouse
Cough number in 3min, as a result statistical analysis are examined.Experimental result is as shown in table 1.
6G the and UA composition of medicine of table 1 draws the influence of cough to mouse ammoniacal liquor
With control group than * P<0.05**P<0.01.
Embodiment 3：Composition of medicine causes the influence of cough to cavy citric acid
Body weight 200-250g cavys are taken, are placed in 4L closed bell jar, 52.5% citric acid is sprayed into 400mmHg pressure,
Spray 1min, more than guinea pig cough number >=10 time qualified in 5min.Qualified cavy is randomly divided into 6 groups (n=10), medicine group
The gained of ig embodiments 1 relieving cough and asthma composition of medicine 500mg/kg, positive controls SC Codeine Hydrochloride 40mg/kg respectively, control
Group ig equivalent distilled water.It is administered once, 1h after medicine, is tested by pre-selection method, records guinea pig cough's incubation period and 5min coughs
Number (when 5min occurs without cough, incubation period, 5min was counted on schedule).As a result examined with statistical software method of analysis of variance.As a result such as table
Shown in 2, composition of medicine can substantially resist the guinea pig cough of citric acid initiation, and each dosage can significantly extend cough latent period (P<
0.05-0.01)。
6G the and UA composition of medicine of table 2 causes the influence of cough to cavy citric acid
With control group than * P<0.05**P<0.01.
Embodiment 4：Relieving cough and asthma composition of medicine causes the influence of Experimental Asthma In Guinea-pigs to histamine
200g or so cavys are taken, in 4L closed glass covers, 2% acetylcholine and 0.4% phosphorus are sprayed into 400mmHg constant pressures
Sour histamine 2ml/4ml mixed liquors, spray 15S every time.Cavy appearance asthmatic twitch incubation period is less than 150S person in record 6min
To be qualified.It is randomly divided into 6 groups (n=10), medicine group 4 groups of relieving cough and asthma composition of medicine 500mg/ that ig embodiments 1 obtain respectively
Kg, positive controls ip aminophylline 100mg/kg, control group ig equivalent distilled water；It is administered once, the 1h (aminophyllines after medicine
After 30min), tested by screening technique.Animal is had a convulsion in record 6min incubation period (person of occurring without in 6min, depending on
Incubation period is 6min).As a result statistical software incubation period is used.Result of the test is as shown in table 3, and composition of medicine group can be obviously prolonged group
Amine triggers the incubation period of cavy twitch, and panting for inducing histamine has significant protective effect (P<0.05).
6G the and UA composition of medicine of table 3 draws the effect of asthma to Guinea Pig Histamine
With control group than * P<0.05**P<0.01.
Embodiment 5：Relieving cough and asthma composition of medicine triggers the influence of cavy allergic asthma to egg protein
200g or so cavys are taken, inject 4% egg protein physiological saline 0.1ml (side) prior to thigh lateral muscle meat, simultaneously
Every guinea pig intraperitoneal injection adsorbs DTP vaccine 1ml sensitized animals.Animal was randomly divided into 6 groups in 2nd day, medicine group ig
The gained of embodiment 1 is relieving cough and asthma composition of medicine 500mg/kg, the steaming of positive controls ig Ketotifens piece 1mg/kg, control group ig equivalent
Distilled water, 1 times/day, continuous 14 days.The 1h after last dose, constant-pressure atomization 20s, Ran Houguan are carried out with 4% egg protein physiological saline
Incubation period, cough number and generation shock that accelerated breathing, expiratory dyspnea, twitch tumble and shock occurs in cavy in 6min is examined to move
Thing number.As a result examined respectively with statistical software method of analysis of variance.Result of the test is as shown in table 4, and composition of medicine triggers to egg protein
Cavy allergic asthma has significant protective effect, can be obviously prolonged the incubation period of expiratory dyspnea and shock caused by egg protein,
Significantly to guinea pig cough caused by anti-egg protein, shock animals number (P is reduced<0.05-0.01).
6G the and UA composition of medicine of table 4 causes the influence of cough to cavy citric acid
With control group than * P<0.05**P<0.01.
Embodiment 6：Influence of the relieving cough and asthma composition of medicine to rat capillary tube method expectoration amount
Body weight is taken as 200g or so rat, after being anaesthetized with yellow Jackets, position fixation is faced upward and keeps flat, cut skin of neck, point
From tracheae, a capillary glass tube is inserted in correct position, juice is discharged into capillary.A capillary is recorded per 30min
Middle secretion liquid column length, after 2h, it is administered by table 5, is re-recorded after medicine with method in 2h capillaries and secrete liquid column length.Statistical comparison,
Using the secretory volume that is averaged per hour before administration as normal value, average secretory volume per hour is as being the 170% of normal value after administration, it is believed that
There are phlegm-dispelling functions.According to said method evaluate the expectorant effect of relieving cough and asthma composition of medicine.Result of the test is as shown in table 5, with control group
Compare, relieving cough and asthma composition of medicine there are significant phlegm-dispelling functions to rat, before * represents after medicine that expectoration amount is medicine per hour
More than 170%.
Influence of the 6G and UA composition of medicine of table 5 to rat capillary tube method expectoration amount
With control group than * P<0.05**P<0.01.
Embodiment 7：Effect of the relieving cough and asthma composition of medicine to the phenol red method eliminating the phlegm of mouse
The body weight of male and female half and half is taken to divide 6 groups for 20g or so mouse.Medicine group is distinguished the gained cough-relieving of gavage embodiment 1 and put down
Breathe heavily composition of medicine 500mg/kg, positive controls ig ammonium chloride 1000mg/kg, control group ig equivalent distilled water.1 time a day, even
It is continuous 3 days, the 30min after last dose, put to death after every mouse ip0.6% phenol red 0.1ml/10g, ip 30min, tracheae is separated, with 38
DEG C 5%NaHCO32ml points of 3 flushing tracheaes of solution.Flushing liquor is collected, is detected with spectrophotometer in 546nm.Result of the test is such as
Shown in table 6, heavy dose can remarkably promote the phenol red discharge of mouse tracheal strips, there is obvious expectorant effect.
Effect of the 6G and UA composition of medicine of table 6 to the phenol red method eliminating the phlegm of mouse
With control group than * P<0.05**P<0.01.
Embodiment 8：The antiinflammatory action of relieving cough and asthma composition of medicine
Body weight 200g healthy rats 72 are taken, make abdominal incision under ether light anaesthesia aseptic condition, in left and right groin
Subcutaneous respectively one 10mg of implantation is through autoclaving, drying and the cotton balls for having 0.2ml penicillin is added dropwise.Post operation rat is divided into 6
Group, start to be administered, relieving cough and asthma composition of medicine 500mg/kg, positive controls ig prednisones obtained by medicine group ig embodiments 1
25mg/kg, control group ig equivalent distilled water, 1 time a day, 10 days.Rat is put to death after last dose 1h, peels off and takes out cotton balls meat
Bud tissue, drying are weighed, and subtract raw cotton ball weight, as granuloma net weight, as a result with SPSS10.0 one-way analysis of variance method
Examine, compare each group granuloma weight, result of the test is as shown in table 7, has significant suppression to make to swollen hyperplasia of rat granuloma hyperplasia
With.
Inhibitory action of the 6G and UA composition of medicine of table 7 to swollen hyperplasia of rat granuloma hyperplasia
With control group than * P<0.05**P<0.01.
Embodiment 9：:Influence of the relieving cough and asthma composition of medicine to murine chronic bronchitis
Healthy mice 80 is taken, model group mouse is put in closed carton, lights two cigarettes, takes out after sootiness and puts at once
In 2-8 DEG C of refrigerator, 30min, each 1 time of daily morning and afternoon are freezed.After 20 days, take a small number of moulding mouse tracheaes, lung with it is normal small
The inspection of mouse malingering is compared, after determining modeling success, by random 6 groups of moulding mouse：Medicine group respectively ig embodiments 1 be prepared only
Cloperastine breathes heavily composition of medicine 500mg/kg, ig dexamethasone 20mg/kg positive controls, the configuration of equivalent distilled water；Daily administration 1
It is secondary, continuous 10 days, mouse is weighed after last dose 1h and is put to death, takes lung to weigh, statistics one-way analysis of variance method is examined.Take
Lung, tracheae are fixed in 10% formalin, make pathological examination, 4 indexs of main detection：Chronic cell infiltration, bronchus
Mucous epithelium hyperplasia, tunica mucosa bronchiorum necrosis come off, goblet cell increases；Each index is with " slight " or " obvious " judgement, respectively
Index is compared with model group, Chi-square Test.Result of the test is as shown in Table 8 and 9；To Chronic Bronchitis Mice lung weight coefficient without bright
Development rings.Each disease inspection index of murine chronic bronchitis is had clear improvement, and especially mouse inflammatory airways cell is soaked
Profit, tunica mucosa bronchiorum epithelial proliferation and goblet cell increase, and have significant inhibitory action, relieving cough and asthma composition of medicine has notable suppression
The effect of murine chronic bronchitis processed.
Inhibitory action of the 6G and UA composition of medicine of table 8 to swollen hyperplasia of rat granuloma hyperplasia
With control group than * P<0.05**P<0.01.
6G the and UA composition of medicine of table 9 is to the inhibitory action to Chronic Bronchitis Mice lung, bronchus pathological change
The * P compared with model group<0.05**P<0.01；The △ P compared with control group<0.01.
Embodiment 10：Relieving cough and asthma composition of medicine paraxylene causes the influence of mice ear
Take healthy mice 60, male and female half and half, random 6 groups.Medicine group respectively ig embodiments 1 be prepared it is relieving cough and asthma
Composition of medicine 500mg/kg, prednisone 5mg/kg, equivalent distilled water control group；1 time a day, continuous 33 days, in last dose 1h
Afterwards, the μ L/ of dimethylbenzene 20 are applied only in every mouse auris dextra, is put to death after 20min, with a diameter of 8mm, card punch is removed two auricles and weighed,
Using the difference of two auricle weight as swelling, as a result examined with statistical software one-way analysis of variance method.Shown in result of the test table 10,
Composition of medicine formula paraxylene causes mice ear to have notable antagonism.
6G the and UA composition of medicine paraxylene of table 10 causes the inhibitory action of mice ear
With control group than * P<0.05**P<0.01.
Embodiment 11：Influence of the relieving cough and asthma composition of medicine to mouse capillary permeability
Healthy mice is grouped at random, respectively the relieving cough and asthma composition of medicine 500mg/kg of the gained of ig embodiments 1, prednisone
5mg/kg, 1 time a day, continuous 3 times；Last dose 1h injects 0.5% Yi Wensilan normal saline solutions after tail vein
(0.1ml/10g), only, put to death, cut after 20min in melted paraxylene 0.03ml/ on the position skin of unhairing of mouse web portion center immediately
Lower abdomen Pigmented Skin, it is put into 7/3 acetone/mixed liquor of normal saline 4ml, soaks 48h, centrifuging and taking supernatant, 610nm ripples
Long colorimetric.Examined with statistical software one-way analysis of variance method, count each group optical density (OD) value.The experimental result such as institute of table 11
Show, the increase of mouse vasopermeability is without obvious antagonism caused by paraxylene.
Effect of the 6G and UA composition of medicine of table 11 to mouse capillary permeability
With control group than * P<0.05**P<0.01.
Embodiment 12：Effect of the relieving cough and asthma composition of medicine to nonspecific immunity function-to normal mouse reticular endothelium system
Carbon particle clearance ability in system (RES) phagocytosis blood flow
Healthy mice is randomly divided into 6 groups, the relieving cough and asthma composition of medicine 500mg/ of gained of medicine group difference ig embodiments 1
Kg, levamisol 100mg/kg, 1 time a day, 7 days, the 1h after last medicine, rat-tail iv india inks 0.1ml/10g, iv after
30s、5min；The μ l of eye socket blood 20 are taken, are placed in equipped with 2ml 0.5%NaHCO3Test tube in, spectrophotometer wavelength 670nm colorimetrics
Detection, as a result examined with statistics one-way analysis of variance method.Result of the test is as shown in table 12, to enhancing normal mouse RES phagocytosiss
Carbon particle clearance ability has certain effect, but DeGrain in blood flow, does not cause the change of Mouse Liver, spleen weight.
6G the and UA composition of medicine of table 12 swallows the effect of carbon particle clearance ability in blood to mouse RES
With control group than * P<0.05**P<0.01.
Embodiment 13：Effect of the relieving cough and asthma composition of medicine to nonspecific immunity function-to normal mouse hemolytic antibody
Generation influences
By the healthy mice random groups of male and female half and half, the relieving cough and asthma composition of medicine of gained of each group difference ig embodiments 1
500mg/kg, 100mg/kg levamisol, 1 time a day, continuous 10 days；It is administered the 3rd day, per the chicken erythrocyte suspensions of mouse ip 4%
0.2ml, animal is immunized.After last dose 1h, eye socket takes the μ l of blood 20, adds in 1ml physiological saline and mixes, then adds
0.5ml 5% chicken erythrocyte suspension, 0.5ml physiological saline and fresh guinea pig serum 1:15 mixed liquor.37 are put into after mixing
30min in DEG C water bath with thermostatic control, stopped reaction in refrigerator, centrifugation, takes supernatant 1ml to add 3ml Dou Shi liquid, stands 10min light splitting afterwards
Photometer 540nm wavelength colorimetric estimations, OD value × 1000 are serum hemolysin value, and one-way analysis of variance method is examined.Experiment
As a result as shown in table 13, there is certain promotion to the generation of normal mouse hemolytic antibody.
The effect that the 6G and UA composition of medicine of table 13 generates to mouse hemolytic antibody
With control group than * P<0.05**P<0.01.
Above-described embodiment is the preferable embodiment of the present invention, but embodiments of the present invention are not by above-described embodiment
Limitation, other any Spirit Essences without departing from the present invention with made under principle change, modification, replacement, combine, simplification,
Equivalent substitute mode is should be, is included within protection scope of the present invention.
Claims (5)
- A kind of 1. compound medicament composition with function of relieving cough and calming asthma, it is characterised in that：The activity of the compound medicament composition Composition is made up of 6-gingerol and ursolic acid.
- A kind of 2. compound medicament composition with function of relieving cough and calming asthma according to claim 1, it is characterised in that：It is described The mass ratio of 6-gingerol and ursolic acid is 1:1~1:10.
- A kind of 3. compound medicament composition with function of relieving cough and calming asthma according to claim 1, it is characterised in that：It is described The mass ratio of 6-gingerol and ursolic acid is 1:1~1:4.
- A kind of 4. compound medicament composition with function of relieving cough and calming asthma according to claim 1, it is characterised in that：This is multiple Prescription compositions also contain pharmaceutically acceptable carrier.
- 5. prepared by a kind of compound medicament composition with function of relieving cough and calming asthma according to any one of Claims 1 to 4 Cough-relieving, antibechic, relieving asthma, eliminating the phlegm, functions of detumescence, relieving inflammation and strengthen immunity medicine in purposes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710604115.5A CN107397738B (en) | 2017-07-19 | 2017-07-19 | Compound pharmaceutical composition with cough and asthma relieving effect and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710604115.5A CN107397738B (en) | 2017-07-19 | 2017-07-19 | Compound pharmaceutical composition with cough and asthma relieving effect and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107397738A true CN107397738A (en) | 2017-11-28 |
| CN107397738B CN107397738B (en) | 2020-06-05 |
Family
ID=60401236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710604115.5A Active CN107397738B (en) | 2017-07-19 | 2017-07-19 | Compound pharmaceutical composition with cough and asthma relieving effect and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107397738B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110585200A (en) * | 2019-07-10 | 2019-12-20 | 郴州市第一人民医院 | Compound pharmaceutical composition with cough and asthma relieving effect and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101648988A (en) * | 2008-08-11 | 2010-02-17 | 天津药物研究院 | Pentacyclic triterpene-28-carboxylic acid amide derivatives containing isoxazole ring, preparation method thereof and application thereof |
| CN101862312A (en) * | 2009-04-14 | 2010-10-20 | 中国中医科学院中药研究所 | New application of 6-gingerol |
-
2017
- 2017-07-19 CN CN201710604115.5A patent/CN107397738B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101648988A (en) * | 2008-08-11 | 2010-02-17 | 天津药物研究院 | Pentacyclic triterpene-28-carboxylic acid amide derivatives containing isoxazole ring, preparation method thereof and application thereof |
| CN101862312A (en) * | 2009-04-14 | 2010-10-20 | 中国中医科学院中药研究所 | New application of 6-gingerol |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110585200A (en) * | 2019-07-10 | 2019-12-20 | 郴州市第一人民医院 | Compound pharmaceutical composition with cough and asthma relieving effect and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107397738B (en) | 2020-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102145126B (en) | Pharmaceutical composition for treating xerophthalmia | |
| CN102302721A (en) | Pharmaceutical composition for treating bronchitis as well as preparation method and use thereof | |
| CN102258614B (en) | Compound propolis composition for treating white diarrhea and chronic respiratory disease and preparation method thereof | |
| DE19953829A1 (en) | New nasal spray containing vitamin C and extracts of Bulpeurum Scorzonerifolium Willd, Radix lastidis Indigotica and Folium lastidis for treating colds, fever and influenza | |
| CN105560884A (en) | Pharmaceutical composition for treating dog pneumonia and preparation method thereof | |
| CN104000197A (en) | Health care product or medicine composition capable of relieving fatigue and preparation method and purpose thereof | |
| CN105764519B (en) | For treating the composition based on plant of cough | |
| CN101322761B (en) | Medicament for treating tracheitis and bronchitic and preparation thereof | |
| CN109645549A (en) | A kind of cigarette of smoking cessation | |
| CN102696910A (en) | Feed composition and traditional Chinese medicine for preventing and treating avian infectious laryngotracheitis | |
| CN107397738A (en) | A kind of compound medicament composition with function of relieving cough and calming asthma and application thereof | |
| CN105412744A (en) | Application of Malong (ephedra and lumbricus) traditional Chinese medicinal composition | |
| CN104491310B (en) | Anti-Fatigue Composition and its preparation method and application | |
| CN108815329A (en) | A kind of Chinese medicine composition and preparation method thereof for treating flu | |
| CN108125237A (en) | A kind of anti-inflammatory health products of kobadrin and its preparation process | |
| CN103393768B (en) | Rhizoma Polygoni Cuspidati and Adenophora stricta combined medicine for cough relieving and panting calming, and preparation and application thereof | |
| CN106668819A (en) | Composition for preventing and treating high swine fever | |
| CN108653645A (en) | A kind of drug and preparation method thereof for treating the enuresis | |
| CN115708859A (en) | Pharmaceutical composition for treating allergic rhinitis and preparation method thereof | |
| CN104398610A (en) | Medicament for treating cough and preparation method thereof | |
| CN114470110A (en) | A Chinese medicinal composition with analgesic effect for treating rhinitis | |
| CN110585200A (en) | Compound pharmaceutical composition with cough and asthma relieving effect and application thereof | |
| CN105687745A (en) | Traditional Chinese medicine composition for treating qi-depression-transforming-into-fire type hyperthyroidism complicating automatic atrial tachycardia | |
| Fraga et al. | Evaluation Of Acute And Chronic Cytotoxicity Of The Hydroethanolic Extract Of Heteropterys Tomentosa A Juss In Rodents: 881 Board# 197 June 1, 2: 00 PM-3: 30 PM | |
| Massey et al. | Cinnamon Supplementation Does Not Increase Fat Oxidation in a Normal Healthy Population: 880 Board# 196 June 1, 2: 00 PM-3: 30 PM |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |